In breast cancer, treatment with a vitamin D analog, BXL1024, reduced breast cancer stem-like cells population CD44+/CD24-/low and CD49f+/CD24-/low, identified as markers of tumor-initiating cells [175]. This evidence concerns the gene CD24 and neoplasm.